Literature DB >> 15262146

Eukaryotic initiation factor 5A-1 (eIF5A-1) as a diagnostic marker for aberrant proliferation in intraepithelial neoplasia of the vulva.

Bernadette M Cracchiolo1, Debra S Heller, Paul M J Clement, Edith C Wolff, Myung-Hee Park, Hartmut M Hanauske-Abel.   

Abstract

OBJECTIVE: The mature eukaryotic translation initiation factor 5A contains the unusual amino acid hypusine, formed post-translationally from a specific lysine residue and essential for proliferation of eukaryotic cells. We hypothesized that the major eIF5A isoform, eIF5A-1, is an in situ biomarker for proliferation. NIH-353, a polyclonal immunoreagent specific for hypusine-containing eIF5A-1, was used to test this proposal in biopsies of vulvar high-grade intraepithelial neoplasia (VIN), characterized by the presence of proliferating cells throughout the thickness of the epithelium. Methods. Formalin-fixed and paraffin-embedded archival samples with an independently established diagnosis of VIN 3 were stained immunohistochemically after antigen retrieval, employing NIH-353 and, for comparison, the standard Ki-67 antibody.
RESULTS: NIH-353 labeled neoplastic keratinocytes throughout the thickness of the epithelium in all VIN 3 samples. Malignant cells in a case of focally invasive squamous cell carcinoma also stained strongly for mature, hypusine-containing eIF5A-1. Epithelium adjacent to these lesions, though still of apparently normal morphology, was immunoreactive throughout its full thickness. At inflammatory foci of lesional sites, solitary reactive lymphocytes were positive, as were individual proliferating cells within dermal appendages. The submucosal stroma lacked reactive cells.
CONCLUSION: NIH-353 identifies mature eIF5A-1 as an in situ biomarker for proliferation. Like Ki-67, this immunoreagent promises broad applicability in histopathological diagnosis and may be helpful in outcome prediction. In contrast to Ki-67, NIH-353 visualizes a molecular target for antineoplastic therapy, and thus may guide the development and clinical testing of drugs that, like the fungicide ciclopirox, inhibit hypusine formation and cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15262146     DOI: 10.1016/j.ygyno.2004.03.018

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  20 in total

Review 1.  DFMO: targeted risk reduction therapy for colorectal neoplasia.

Authors:  Christina M Laukaitis; Eugene W Gerner
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-08       Impact factor: 3.043

Review 2.  Translational control in cancer.

Authors:  Deborah Silvera; Silvia C Formenti; Robert J Schneider
Journal:  Nat Rev Cancer       Date:  2010-04       Impact factor: 60.716

Review 3.  Targeting the polyamine-hypusine circuit for the prevention and treatment of cancer.

Authors:  Shima Nakanishi; John L Cleveland
Journal:  Amino Acids       Date:  2016-06-29       Impact factor: 3.520

4.  A hypusine-eIF5A-PEAK1 switch regulates the pathogenesis of pancreatic cancer.

Authors:  Ken Fujimura; Tracy Wright; Jan Strnadel; Sharmeela Kaushal; Cristina Metildi; Andrew M Lowy; Michael Bouvet; Jonathan A Kelber; Richard L Klemke
Journal:  Cancer Res       Date:  2014-09-26       Impact factor: 12.701

Review 5.  The translation factor eIF5A and human cancer.

Authors:  Michael B Mathews; John W B Hershey
Journal:  Biochim Biophys Acta       Date:  2015-05-13

Review 6.  eIF5A isoforms and cancer: two brothers for two functions?

Authors:  M Caraglia; M H Park; E C Wolff; M Marra; A Abbruzzese
Journal:  Amino Acids       Date:  2011-12-03       Impact factor: 3.520

7.  Inhibition of glycogen phosphorylation induces changes in cellular proteome and signaling pathways in MIA pancreatic cancer cells.

Authors:  Danjun Ma; Jiarui Wang; Yingchun Zhao; Wai-Nang Paul Lee; Jing Xiao; Vay Liang W Go; Qi Wang; Robert R Recker; Gary Guishan Xiao
Journal:  Pancreas       Date:  2012-04       Impact factor: 3.327

8.  Proteomic analysis of cervical cancer cells treated with suberonylanilide hydroxamic acid.

Authors:  Jianxiong He; Canhua Huang; Aiping Tong; Bin Chen; Zhi Zeng; Peng Zhang; Chunting Wang; Yuquan Wei
Journal:  J Biosci       Date:  2008-12       Impact factor: 1.826

9.  Regulation of expression of deoxyhypusine hydroxylase (DOHH), the enzyme that catalyzes the activation of eIF5A, by miR-331-3p and miR-642-5p in prostate cancer cells.

Authors:  Michael R Epis; Keith M Giles; Felicity C Kalinowski; Andrew Barker; Ronald J Cohen; Peter J Leedman
Journal:  J Biol Chem       Date:  2012-08-20       Impact factor: 5.157

10.  Inhibition of HIV-1 gene expression by Ciclopirox and Deferiprone, drugs that prevent hypusination of eukaryotic initiation factor 5A.

Authors:  Mainul Hoque; Hartmut M Hanauske-Abel; Paul Palumbo; Deepti Saxena; Darlene D'Alliessi Gandolfi; Myung Hee Park; Tsafi Pe'ery; Michael B Mathews
Journal:  Retrovirology       Date:  2009-10-13       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.